The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective

Current Medical Research and Opinion

Volumn 20, Issue 11, 2004, Pages 1805-1814

  Vicente Herrero, Teofila ^a   Burke, Thomas A ^b   Laínez, Miguel J A ^c  

^a Correos y Telegrafos de Espana ^*  (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Costs and cost analysis; Occupational health; Productivity; Rizatriptan

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CAFERGOT; DIHYDROERGOTAMINE; DIPYRONE MAGNESIUM; ERGOTAMINE; FLUNARIZINE; IBUPROFEN; METOCLOPRAMIDE; NADOLOL; NAPROXEN; NICARDIPINE; PARACETAMOL; PAROXETINE; PROPRANOLOL; PROPYPHENAZONE; RIZATRIPTAN; ROFECOXIB; TONOPAN;

ABSENTEEISM; ADULT; CONTROLLED STUDY; COST; DAILY LIFE ACTIVITY; EMPLOYEE; EMPLOYER; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PALLIATIVE THERAPY; PATIENT COUNSELING; POSTAL MAIL; PRESCRIPTION; PRODUCTIVITY; REVIEW; SOCIAL BEHAVIOR; SPAIN; TENSION HEADACHE;

ABSENTEEISM; ADULT; COSTS AND COST ANALYSIS; COUNSELING; EFFICIENCY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIGRAINE DISORDERS; OCCUPATIONAL HEALTH SERVICES; POSTAL SERVICE; SEROTONIN AGONISTS; SPAIN; TRIAZOLES; TRYPTAMINES;

EID: 10044256399     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X10151     Document Type: Review

References (26)

1. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997;48(Suppl. 3):S4-9
2. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43 (Suppl. 3):S6-10
3. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM 1996;89:77-84
4. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992;2:103-15
5. van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995;7:170-9
6. Warshaw LJ, Burton WN. Cutting the costs of migraine: role of the employee health unit. J Occup Environ Med 1998;40:943-53
7. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(Suppl. 7):1-96
8. Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:231-44
9. McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. New York, NY: Chapman and Hall, 1989
10. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. 2nd edn. Gary, NC: SAS Institute, 2000
11. Bigal ME, Moraes FA, Fernandes LC, Bordini CA, Speciali JG. Indirect costs of migraine in a public Brazilian hospital. Headache 2001;41:503-8
12. Pop PH, Gierveld CM, Karis HA, Tiedink HG. Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 2002;9:171-4
13. Michel P, Dartigues JF, Lindoulsi A, Henry P. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997;37:71-8
14. Schneider WJ, Furth PA, Blalock TH, Sherrill TA. A pilot study of a headache program in the workplace. The effect of education. J Occup Environ Med 1999;41:202-9
15. Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002;42:93-8
16. Leira R, Dualde E, del Barrio H, Machuca M, Lopez-Gil A. Almotriptan versus rizatriptan in patients with migraine in Spain. Headache 2003;43:734-41
17. Streator SE, Shearer SW. Pharmacoeconomic impact of the injectable sumatriptan on migraine-associated healthcare costs. Am J Manag Care 1996;2:139-43
18. Legg RF, Sclar DA, Nemec NL, Tarnai J, Mackowiak JI. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997;3:117-22
19. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patents with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159:857-63
20. Burton WN, Morrison A, Wertheimer AI. Pharmaceuticals and worker productivity loss: a critical review of the literature. J Occup Environ Med 2003;45:610-21
21. Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845-54
22. Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999;19:497-502
23. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000;20:830-834
24. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-8
25. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9
26. Garcia-del-Pozo J, Carvajal A, Grajal C, Vera E, del Pino A. Antimigraine drug consumption in Spain (1990-2000). Acta Neurol Scand 2003;107:158-60